Kilitch Drugs (India)

₹191.10As of Sun 8 Nov 2026, 12:00 UTC

NSE:KILITCHHealthcare

Country India

PE (Fwd) 17.01

TSR 10Y CAGR 23.73%

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.34

PE TTM 21.44

TSR TTM (1.58%)

Mkt cap ₹7.058B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹212

10.70%

(58.43%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

2.355

Revenue₹B

—

1.142

1.396

1.544

1.983

2.355

2.657

19.82%

18.74

Revenue growth%

—

22.20

10.58

28.47

18.74

12.83

20.47

—

46.19

Gross margin%

—

41.01

45.98

48.57

46.90

46.19

46.35

46.19

14.55

Operating margin%

—

8.77

10.64

14.45

14.72

14.55

14.61

14.45

12.81

Net margin%

—

6.45

7.48

9.46

13.46

12.81

12.84

9.46

21.44

P/E ratio (avg)x

—

36.83

23.77

30.85

10.20

21.67

18.95

23.77

18.87

EV/EBITx

—

27.09

16.72

20.20

9.323

19.08

16.66

19.08

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

8.91

EPS₹

—

2.37

3.35

4.58

16.60

8.91

10.08

39.31%

—

(46.31)

EPS growth%

—

41.67

36.71

262.25

(46.31)

13.11

39.19

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

Div yield (avg)%

—

Payout ratio%

—

33.84

Shares (diluted)M

—

31.13

31.16

31.86

16.08

33.84

◌33.84

2.11%

(110.43)

Buyback yield%

—

(0.10)

(2.23)

49.52

(110.43)

◌—

(1.17)

—

D/E ratiox

—

6.467

Enterprise value₹B

—

2.713

2.483

4.504

2.722

6.537

6.467

24.59%

—

LT debt₹M

—

Peers (US$72.41M)

Cap (US$)

ZIM Laboratories…

74.98M

326.5x

Wanbury Limited

74.06M

14.35x

Valiant Laboratories…

67.15M

35.96x

Laboratorios Richmond…

72.91M

9.009x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

6.162

5.792

Own earn%

—

Sh yield%

(110.43)

(1.17)

Owners

Insiders/Inst%

38.61

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

9–15

$1 testx

—

Incr. ROIC%

—

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹2.355B

19.82%

1.00×

Cost of revenue

₹1.267B

17.10%

0.91×

Operating expenses

₹745.1M

19.26%

0.98×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m